Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

Accurate evaluation of the response to preoperative treatment enables the provision of a more appropriate personalized therapeutic schedule for locally advanced rectal cancer (LARC), which remains an enormous challenge, especially neoadjuvant immunotherapy plus chemoradiotherapy (nICRT).